These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 18552880)

  • 1. Brivaracetam: a rational drug discovery success story.
    Rogawski MA
    Br J Pharmacol; 2008 Aug; 154(8):1555-7. PubMed ID: 18552880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A.
    Matagne A; Margineanu DG; Kenda B; Michel P; Klitgaard H
    Br J Pharmacol; 2008 Aug; 154(8):1662-71. PubMed ID: 18500360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levetiracetam: preliminary efficacy in generalized seizures.
    Kasteleijn-Nolst Trenité DG; Hirsch E
    Epileptic Disord; 2003 May; 5 Suppl 1():S39-44. PubMed ID: 12915340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levetiracetam.
    Krishna K; Raut AL; Gohel KH; Dave P
    J Assoc Physicians India; 2011 Oct; 59():656-8. PubMed ID: 22479748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy.
    Klitgaard H; Matagne A; Gobert J; Wülfert E
    Eur J Pharmacol; 1998 Jul; 353(2-3):191-206. PubMed ID: 9726649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levetiracetam: the preclinical profile of a new class of antiepileptic drugs?
    Klitgaard H
    Epilepsia; 2001; 42 Suppl 4():13-8. PubMed ID: 11564119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment.
    Klitgaard H; Matagne A; Nicolas JM; Gillard M; Lamberty Y; De Ryck M; Kaminski RM; Leclercq K; Niespodziany I; Wolff C; Wood M; Hannestad J; Kervyn S; Kenda B
    Epilepsia; 2016 Apr; 57(4):538-48. PubMed ID: 26920914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brivaracetam for the treatment of epilepsy.
    Klein P; Tyrlikova I; Brazdil M; Rektor I
    Expert Opin Pharmacother; 2016; 17(2):283-95. PubMed ID: 26760311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties.
    Gillard M; Fuks B; Leclercq K; Matagne A
    Eur J Pharmacol; 2011 Aug; 664(1-3):36-44. PubMed ID: 21575627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam.
    Kaminski RM; Gillard M; Leclercq K; Hanon E; Lorent G; Dassesse D; Matagne A; Klitgaard H
    Epilepsia; 2009 Jul; 50(7):1729-40. PubMed ID: 19486357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.
    Lynch BA; Lambeng N; Nocka K; Kensel-Hammes P; Bajjalieh SM; Matagne A; Fuks B
    Proc Natl Acad Sci U S A; 2004 Jun; 101(26):9861-6. PubMed ID: 15210974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brivaracetam: First Global Approval.
    Markham A
    Drugs; 2016 Mar; 76(4):517-22. PubMed ID: 26899665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy.
    Gower AJ; Hirsch E; Boehrer A; Noyer M; Marescaux C
    Epilepsy Res; 1995 Nov; 22(3):207-13. PubMed ID: 8991787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The preclinical discovery and development of brivaracetam for the treatment of focal epilepsy.
    Russo E; Citraro R; Mula M
    Expert Opin Drug Discov; 2017 Nov; 12(11):1169-1178. PubMed ID: 28829199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preliminary efficacy of levetiracetam in monotherapy.
    Ben-Menachem E
    Epileptic Disord; 2003 May; 5 Suppl 1():S51-5. PubMed ID: 12915342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levetiracetam: treatment in epilepsy.
    Ben-Menachem E
    Expert Opin Pharmacother; 2003 Nov; 4(11):2079-88. PubMed ID: 14596661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: A prospective explorative study with a historical control group.
    Maschio M; Zarabla A; Maialetti A; Fabi A; Vidiri A; Villani V; Giannarelli D
    Epilepsy Behav; 2017 Aug; 73():83-89. PubMed ID: 28623754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.
    Wood MD; Gillard M
    Epilepsia; 2017 Feb; 58(2):255-262. PubMed ID: 28012162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An assessment of levetiracetam as an anti-epileptic drug.
    Jain KK
    Expert Opin Investig Drugs; 2000 Jul; 9(7):1611-24. PubMed ID: 11060765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Piracetam and levetiracetam, two pyrrolidone derivatives, exert antidystonic activity in a hamster model of paroxysmal dystonia.
    Löscher W; Richter A
    Eur J Pharmacol; 2000 Mar; 391(3):251-4. PubMed ID: 10729365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.